Company Celldex Therapeutics, Inc. Nasdaq

Equities

US15117B1035

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Other Biotechnology & Medical Research

Inactive Instrument

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Companyâs bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.

USD in Million	2022	Weight	2023	Weight	Delta
Novel Therapeutics 100.0 %	2	100.0 %	7	100.0 %	+192.02%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	2	100.0 %	7	100.0 %	+192.02%

Managers	Title	Age	Since
Tibor Keler FOU	Founder	65	82-12-31
Anthony Marucci FOU	Founder	62	82-12-31
Sam Martin DFI	Director of Finance/CFO	53	09-03-31
Diane Young CTO	Chief Tech/Sci/R&D Officer	68	19-07-07
Sarah Boylan Cavanaugh ADM	Chief Administrative Officer	49	12-07-31
Freddy Jimenez LAW	General Counsel	55	16-01-31
Margo Heath-Chiozzi LAW	General Counsel	67	17-10-02
Richard Wright PRN	Corporate Officer/Principal	60	11-12-31
Elizabeth Crowley PRN	Corporate Officer/Principal	52	08-12-31
Ronald A. Pepin PRN	Corporate Officer/Principal	68	11-07-06

Members of the board	Title	Age	Since
Herbert Conrad BRD	Director/Board Member	91	08-02-29
Cheryl L. Cohen BRD	Director/Board Member	58	22-06-15
Harry H. Penner BRD	Director/Board Member	78	96-12-31
James Marino BRD	Director/Board Member	74	17-03-07
Karen Lipton Shoos CHM	Chairman	70	01-04-30
Anthony Marucci FOU	Founder	62	82-12-31
Garry Neil BRD	Director/Board Member	70	22-06-15
Keith L. Brownlie BRD	Director/Board Member	71	17-06-14
Rita Jain BRD	Director/Board Member	62	23-02-15

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	64,403,377	64,179,723 ( 99.65 %)	0	99.65 %

Name	Equities	%	Valuation
Fidelity Management & Research Co. LLC 10.94 %	7,050,409	10.94 %	296 M $
Wellington Management Co. LLP 10.05 %	6,476,561	10.05 %	272 M $
Eventide Asset Management LLC 5.635 %	3,630,013	5.635 %	152 M $
BlackRock Advisors LLC 5.405 %	3,481,916	5.405 %	146 M $
RTW Investments LP 5.376 %	3,463,201	5.376 %	145 M $
POLAR CAPITAL HOLDINGS PLC 4.868 %	3,135,871	4.868 %	132 M $
Vanguard Fiduciary Trust Co. 4.729 %	3,046,331	4.729 %	128 M $
Kynam Capital Management LP 4.666 %	3,005,904	4.666 %	126 M $
Point72 Asset Management LP 4.278 %	2,756,122	4.278 %	116 M $
Bellevue Asset Management AG 3.751 %	2,416,296	3.751 %	101 M $

Celldex Therapeutics, Inc.

Perryville III Building 53 Frontage Road

08827, Hampton

+908 200 7500

http://www.celldex.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	-0.02%	42.11B
LONZA GROUP AG	+43.29%	40.08B
MODERNA, INC.	+5.04%	40B
CELLTRION, INC.	-11.32%	26.87B
ICON PUBLIC LIMITED COMPANY	+5.25%	24.58B
ALNYLAM PHARMACEUTICALS, INC.	-23.83%	18.44B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.62%	11.94B
MEDPACE HOLDINGS, INC.	+22.75%	11.66B
UNITED THERAPEUTICS CORPORATION	+6.44%	11.01B

Other Biotechnology & Medical Research